RNAZ TransCode Therapeutics, Inc.
Healthcare$6.24+2.04%ClosedMarket Cap: $5.9M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
0.04
P/S
0.00
EV/EBITDA
0.23
DCF Value
$30.08
FCF Yield
-84225.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-99.4%
ROA
-25.7%
ROIC
-21.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-7.3M | $-17.8M | $— | — |
| Q4 null | $0.00 | NaN% | $-16.0M | $-13.4M | $— | — |
| FY null | $0.00 | NaN% | $-28.0M | $-34.7M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-4.6M | $-4.9M | $— | — |
| Q2 null | $0.00 | NaN% | $-4.2M | $-4.3M | $— | — |
| Q1 null | $0.00 | NaN% | $-3.2M | $-12.1M | $— | — |
| Q4 null | $0.00 | NaN% | $-5.1M | $-5.9M | $— | — |
| FY null | $0.00 | -Infinity% | $-15.7M | $-16.8M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-2.2M | $-2.3M | $— | — |
| Q2 null | $0.00 | NaN% | $-5.1M | $-5.2M | $— | — |
| Q1 null | $0.00 | NaN% | $-3.3M | $-3.3M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-4.1M | $-4.1M | $-761.16 | — |